Congress Center Basel, 10 - 11 September 2019
Chairs
Thomas Vorherr (Novartis Pharma AG, Basel, Switzerland)
Roderich Süssmuth (Technical University of Berlin, Germany)
Tuesday, 10 September 2019
| 10.00 | Playmolecule, a repository of deep learning based applications for biomolecule design Franck Chevalier (Acellera, Barcelona, Spain) |
| 10.30 | Optimization of the lipopeptide arylomycin natural product into Gram-negative antibiotics Christopher Heise (Genentech Research & Early Development, San Francisco, United States) |
| 11.00 | Break |
| 11.30 | Activation of the Hippo pathway via targeting of transcription factor TEAD using designed tertiary protein structure mimetics Helene Adihou (Astra Zeneca, Dortmund, Germany) |
| 12.00 | Elimination of Aβ oligomers by the orally available all-D-peptide PRI-002 reverses cognition deficits and decelerates neurodegeneration Dieter Willbold (University of Düsseldorf, Germany) |
| 12.30 | Lunch break and Industry Symposium |
| 14.00 | PLENARY LECTURE The chemical evolution of endocrine hormones Richard DiMarchi (University of Indiana, Bloomington, United States) |
| 15.00 | Break |
| 15.30 | Peptide platforms for therapy and imaging: The first total synthesis of amanitin for ADCs and one-step 18F-labeling PET-oncology David Perrin (University of British Columbia, Vancouver, Canada) |
| 16.00 | Virobiome derived anti-inflammatory short peptides Michael Ruff (Creative BioPeptides) |
Wednesday, 11 September 2019
| 10.00 | Exotic side chain-to-side-chain cyclization modes in octreotide analogs for tumor pretargeting Anna Maria Papini (University of Florence, Italy) |
| 10.30 | Peptide-based radiopharmaceuticals for cancer imaging and therapy Agonist or Antagonist? Does it really matter? Melpomeni Fani (University Hospital Basel, Switzerland) |
| 11.00 | Break |
| 11.30 | Vancomycin regains effectiveness for resistant bacteria by conjugation to cationic peptides Walter Mier (University of Heidelberg, Germany) |
| 12.00 | Peptide discovery at protagonist therapeutics: A platform yielding multiple clinical candidates Mark Smythe (Protagonist, Newark, United States) |
| 12.30 | Lunch break and Industry Symposium |
| 14.00 | Disulfide-rich peptide production Mike Pennington (AmbioPharm, North Augusta, United States) |
| 14.30 | A new green solvent for solid phase peptide synthesis Jon Collins (CEM, Matthews, United States) |
| 15.00 | Break |
| 15.30 | Synthetic immune system engagers target cancer cells and prevent tumor formation Christian Becker (University of Vienna, Austria) |
| 16.00 | Discovery and clinical development of an inhaled cyclic peptide elastase inhibitor for the treatment of cystic fibrosis Roxana Drake & Marc Thommen (Santhera Pharmaceuticals CH Ltd., Pratteln, Switzerland) |
The programme indicated maybe subject to change!
Website Basel Life: https://www.basellife.org/
David Spichiger, SCS
17.04.2019